Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
- Status
- RECRUITING
- Phase
- PHASE3
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Status
- RECRUITING
- Phase
- PHASE3
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
- Status
- RECRUITING
- Phase
- PHASE3
The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis
- Status
- RECRUITING
- Phase
- PHASE2
Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
- Status
- RECRUITING
- Phase
- PHASE3
Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
- Status
- RECRUITING
- Phase
- PHASE2
Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
- Status
- RECRUITING
- Phase
- PHASE2
Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular Carcinoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents
- Status
- RECRUITING
- Phase
- PHASE1
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
- Status
- RECRUITING
- Phase
- PHASE3